Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of N-Benzylaniline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH3 known ✓ | Q9ULD8 | 1/20 | 0.61 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | LTA4H | P09960 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | PTPRF | P10586 | 1/20 | 0.57 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22628164 | 0.97 | HTT (0.71) | HTTCYP3A4CYP1A2KCNH3MEN1 | |
| N-Benzylaniline SCHEMBL7840 | 0.97 | HTT (0.71) | HTTCYP3A4CYP1A2KCNH3MEN1 | |
| N-Benzylaniline SCHEMBL27620362 | 0.95 | HTT (0.68) | HTTCYP3A4CYP1A2KCNH3MEN1 | |
| N-Benzylaniline SCHEMBL357137 | 0.95 | HTT (0.68) | HTTCYP3A4CYP1A2KCNH3MEN1 | |
| N-Benzylaniline SCHEMBL2176624 | 0.95 | HTT (0.68) | HTTCYP3A4CYP1A2KCNH3MEN1 | |
| N-Benzylaniline SCHEMBL10963734 | 0.92 | HTT (0.65) | HTTCYP3A4CYP1A2KCNH3MEN1 | |
| SCHEMBL1924100 | 0.92 | HTT (0.78) | HTTCYP3A4CYP1A2MEN1CYP2C9 | |
| SCHEMBL2065031 | 0.92 | CYP1A2 (0.69) | HTTCYP3A4CYP1A2MEN1CYP2C9 | |
| SCHEMBL2741249 | 0.88 | HTT (0.67) | HTTCYP3A4CYP1A2KCNH3MEN1 | |
| N-Benzylaniline SCHEMBL19915239 | 0.88 | HTT (0.61) | HTTCYP3A4CYP1A2KCNH3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108640882-A | A kind of continuous production three（Tribromophenoxy）The method and its production equipment of triazine | 山东旭锐新材有限公司 | 2018-10-12 | — | — | CN | claimed |
| WO-2023069613-A1 | ARYLIMIDAMIDES FOR USE IN TREATMENT OF CANCERS | OHIO STATE INNOVATION FOUNDATION (US) | 2023-04-27 | — | — | WO | disclosed |
| CN-104140379-B | Fluorine-containing extractant and application thereof | 中国科学院上海有机化学研究所 | 2017-05-10 | — | — | CN | disclosed |
| CN-103130662-A | Cationic water cosolvent with V-type configuration, polymer thereof, synthetic method and application thereof | CHINESE ACAD TECH INST PHYSICS | 2013-06-05 | — | — | CN | disclosed |
| US-7671196-B2 | Diazepinoquinolines, synthesis thereof, and intermediates thereto | WYETH LLC (US) | 2010-03-02 | — | — | US | disclosed |
| EP-1907390-A2 | DIAZEPINOQUINOLINES, SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | Wyeth a Corporation of the State of Delaware (US) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007016029-A2 | DIAZEPINOQUINOLINES, SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | WYETH (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20070027142-A1 | Diazepinoquinolines, synthesis thereof, and intermediates thereto | WYETH (US) | 2007-02-01 | — | — | US | disclosed |
| WO-2005097883-A2 | METHOD OF PRODUCING A CROSSLINKED COATING IN THE MANUFACTURE OF INTEGRATED CIRCUITS | KING INDUSTRIES, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| US-20050215713-A1 | Method of producing a crosslinked coating in the manufacture of integrated circuits | KING INDUSTRIES, INC. | 2005-09-29 | — | — | US | disclosed |
| US-5430062-A | Combretastatin analogues; inhibition of tubulin polymerization and colchicine binding; antitumor,-mitotic and -neoplastic agents | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1995-07-04 | — | — | US | disclosed |
| EP-0641301-A1 | STILBENE DERIVATIVES AS ANTICANCER AGENTS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1995-03-08 | — | — | EP | disclosed |
| WO-1993023357-A1 | STILBENE DERIVATIVES AS ANTICANCER AGENTS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1993-11-25 | — | — | WO | disclosed |
| US-4132822-A | Laminates containing polyester resin finishes | PPG INDUSTRIES, INC. (US) | 1979-01-02 | — | — | US | disclosed |
| US-4020193-A | Method of forming a non-glossy film | PPG INDUSTRIES, INC. (US) | 1977-04-26 | — | — | US | disclosed |
| US-3953622-A | PEROXIDE CATALYST, GELATION, COATING, ULTRAVIOLET LIGHT | PPG INDUSTRIES, INC. (US) | 1976-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027142-A1 | Diazepinoquinolines, synthesis thereof, and intermediates thereto | HTR2C, HTR3B, HTR2A | KCNH3 653/4885CA2 4114/4885HTT 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.